Prollenium Medical Technologies Inc. Launch First and Only Dermal Filler Manufacturing Facility in Canada
12 Jun, 2013, 08:00 ET
AURORA, ON, June 12, 2013 /CNW/ - Prollenium Medical Technologies Inc. has opened its new facility, just north of Toronto, making it the only manufacturer of dermal fillers for tissue reconstruction in Canada. Prollenium is widely recognized as a leading manufacturer of medical devices used in cosmetic and plastic surgery treatments worldwide.
Prollenium focuses its efforts on the research, marketing and sales of biomaterials that can be used in a wide array of tissue reconstruction applications. "This new facility now offers a much more proactive opportunity for us to meet changes in the marketplace," says Chief Executive, Ario Khoshbin, "Allowing us to better innovate our products and introduce new product extension lines to the market." Manufacturing its products in-house allows Prollenium to maintain principles of excellence and trust in the manufacture and design of their products.
The new facility is the only automated syringe manufacturing and packaging line of viscous gels for implantation in Canada. It employs a fully automated process in a clean room environment with sterilization, packaging and quality control taking place in-house. The site is ISO 13485 registered as well as Health Canada and CE approved. It also houses the company's Marketing, Sales and R&D teams. With continued success and the opening of the new facility, Prollenium has increased its workforce significantly in just the past few years.
"Here at Prollenium, we invest heavily in the research and development of highly innovative products to offer an ever-charging market," says Senior Vice President Khasha Ighanian. "It is a great accomplishment to have the ability to design and produce those products here in Canada under our own roof." Prollenium has an extensive product line extending from dermal fillers to skincare and revitalization. The company also has a focus on the therapeutic field. The new location yields a capacity exceeding over 2 million syringes annually.
For more information, please visit www.prollenium.com
Prollenium Medical Technologies Inc. is a Canadian-based company, founded in 2002, dedicated to the research, design, manufacture and distribution of implantable polymers in the pharmaceutical/dermatological industry. The company is committed to providing innovative products worldwide that are safe and viable. Flagship product lines include Revanesse®, Phiderma® and RheoVital™.
SOURCE: Prollenium Medical Technologies Inc.
For further information:
Contact: Brittany Edwards
Share this article